Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Implementing Informed Treatment Options in Antipsychotic Therapy


neuroscienceCME Live and On Demand

Premiere Date: Wednesday, April 4, 2012

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Social Workers (NASW)
  4. Certified Case Managers (CCMC)
  5. Pharmacists (ACPE)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, April 4, 2013
Note: Credit Is No Longer Available


John W. Newcomer, MDJohn W. Newcomer, MD (Moderator)
Senior Associate Dean for Clinical Research
Leonard M. Miller Professor of Psychiatry and Behavioral Sciences
Leonard M. Miller School of Medicine
University of Miami
Miami, FL

John M. Kane, MDJohn M. Kane, MD 
Senior Vice President, Behavioral Health Services, Northwell Health
New Hyde Park, NY
Chairman, Department of Psychiatry, Zucker Hillside Hospital
Glen Oaks, NY
Professor and Chairman of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY

Herbert Y. Meltzer, MDHerbert Y. Meltzer, MD 
Professor, Psychiatry and Physiology
Director, Translational Neuropharmacology Program
Northwestern University Feinberg School of Medicine
Chicago, IL
Director, Schizophrenia Research Program
Centerstone Mental Health System
Nashville, TN

Statement of Need

Bridging the science-to-service gap in the treatment of patients with schizophrenia means educating clinicians about the advances in clinical management of these patients. If clinicians are to make informed medication choices for their patients, clinicians need to embrace the science of receptors and understand various receptor profiles. This understanding translates into useful knowledge regarding the negative and cognitive symptoms of schizophrenia. This knowledge also informs the pharmacotherapy, with a watchful eye for adverse events and possible metabolic issues.(1) Viewing the treatment of individuals with schizophrenia in a broader context of multimodal care that includes pharmacology, family involvement, cognitive and psychosocial education can make a significant difference in the quality of life of these patients.(2)

This neuroscienceCME Live and On Demand program will demonstrate to clinicians that there is an array of informed pharmacologic and non-pharmacologic treatment options in the management of individuals with schizophrenia.

  1. Cutler A, Ball S, Stahl SM. Dosing atypical antipsychotics. CNS Spectr. 2008;13(5 Suppl 9):1-16. PMID: 18496483.
  2. Kern RS, Glynn SM, Horan WP, Marder SR. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. 2009;35(2):347-361. PMID: 19176470.

Activity Goal

The goal of this activity is to bring the latest science into clinical practice to assist practitioners in exploring treatment options while making informed choices for individuals with schizophrenia.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Evaluate currently approved antipsychotic agents by contrasting differences in their pharmacologic mechanisms and associated therapeutic and side effects.
  • Analyze the current evidence and approaches to antipsychotic switch strategies, evaluate patients who may be appropriate candidates for switching, and implement these strategies as part of an overall individualized treatment plan.
  • Integrate best practices that include family involvement and psychoeducation as part of an individualized, multimodal treatment strategy for persons with schizophrenia.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Review the currently approved antipsychotic agents and the symptoms that they target and common side effects.
  • Describe the need for switch strategies with antipsychotic medications.
  • Define the elements of a multimodal treatment strategy for patients with schizophrenia.

Financial Support

Supported by an educational grant from Sunovion Pharmaceuticals Inc.

Target Audience

Primary Target Audience: Psychiatrists, primary care physicians
Secondary Target Audience: Physician assistants, nurses, nurse practitioners, pharmacists, social workers and certified case managers

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 1.5 continuing education contact hour.

CCMC Credit (Certified Case Managers):
This program has been approved for 1.5 hours by the Commission for Case Manager Certification (CCMC).

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number: 0376-0000-12-006-L01-P (live programs)
0376-0000-12-006-H01-P (recorded programs)
Activity Type: knowledge-based

Post-tests, credit request forms, and activity evaluations must be completed online at (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Newcomer has disclosed that he has received research grants from the National Institutes of Mental Health; Bristol-Myers Squibb Company and Pfizer Inc. He serves as a Consultant/Data Safety Monitoring Committee for AstraZeneca Pharmaceuticals; BioVail Pharmaceuticals, Inc.; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Consultant to Litigation; Dainippon Sumitomo Pharma Co, Ltd.; H. Lundbeck A/S; Obecure Ltd; Otsuka America Pharmaceuticals, Inc; Merck & Col., Inc.; Teva Pharmaceuticals USA; VIVUS Inc.; Inc. He receives royalties, patents or other income from Jones and Barlett Publishing.

Dr. Kane has disclosed that he serves on the speakers bureau of Bristol-Myers Squibb and Company; Merck & Co., Inc.; and Otsuka Ameria, Inc. He serves as a consultant for Alkermes; Amgen Inc.; Bristol-Myers Squibb; Cephalon, Inc.; Eli Lilly and Company; Lundbeck; Intracellular Therapies, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Merck & Co.; Novartis Corporation; Otsuka America, Inc.; Pierre Fabre Pharmaceuticals Inc.; Roche; and Sunovion. He is a shareholder of MedAvante Inc.

Dr. Meltzer has disclosured that he has received research grants from BioLineRx; Dainippon Sumitomo Pharma Co, Ltd.; Sunovion Pharmaceuticals; Janssen Pharmaceuticals; Otsuka America Inc. He serves as a consultant for Acadia; Alkermes; Amgen Inc.; BioLineRx; Lunbeck; Merck; Novartis Pharmaceuticals; Jazz Pharmaceuticals; Teva Pharmaceuticals USA. He is a stockholder in Acadia and GlaxoSmithKline.

Tony Graham, MD (content/peer reviewer) has no disclosures to report.

Nancy Jennings, MSN, MBA, MHA, RNC (content/peer reviewer) has no disclosures to report.

Ruth Cody, BSN, RN-BC (content/peer reviewer) has no disclosures to report.

Robert Kennedy (planning committee) has no disclosures to report.

Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.

Unlabeled Use Disclosure

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, and Sunovion do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download